皓元医药(688131) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 reached ¥563,514,257.78, an increase of 13.80% year-over-year, while year-to-date revenue totaled ¥1,619,063,344.90, up 17.65% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2024 was ¥72,940,284.56, a significant increase of 212.93% year-over-year, with year-to-date net profit at ¥143,347,970.22, up 21.31%[4] - The net profit excluding non-recurring gains and losses for Q3 2024 was ¥63,060,727.54, reflecting a 194.47% increase year-over-year, while year-to-date this figure reached ¥129,556,520.04, up 21.04%[4] - Basic and diluted earnings per share for Q3 2024 were both ¥0.35, representing a 218.18% increase compared to the same period last year[4] - Total operating revenue for the first three quarters of 2024 reached CNY 1,619,063,344.90, an increase of 17.7% compared to CNY 1,376,113,868.75 in the same period of 2023[22] - Net profit for the first three quarters of 2024 was CNY 140,779,655.41, representing a 20.6% increase from CNY 116,758,100.59 in 2023[23] - Total comprehensive income for Q3 2024 was CNY 154,814,754.70, compared to CNY 119,459,751.34 in Q3 2023, indicating a growth of 29.6%[24] Assets and Liabilities - Total assets as of the end of Q3 2024 were ¥4,683,502,645.40, an increase of 11.72% from the end of the previous year[6] - The total current assets reached CNY 2,376,880,587.70, up from CNY 2,188,265,705.87, indicating an increase of about 8.6% year-over-year[19] - The total liabilities increased to CNY 1,961,782,221.72 from CNY 1,665,929,876.55, which is an increase of approximately 17.7%[20] - The company's equity attributable to shareholders reached CNY 2,704,179,683.13, up from CNY 2,509,078,803.36, representing a growth of about 7.8%[20] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥159,008,040.52, reflecting improved cash management practices[11] - The net cash flow from operating activities was ¥159,008,040.52, a significant improvement compared to the negative ¥193,898,787.78 from the previous year[26] - The total cash outflow from investing activities was ¥199,118,409.29, down from ¥1,059,166,343.78 in the same period last year[26] - The cash flow from investment activities showed a net outflow of ¥179,205,237.25, an improvement from the previous year's outflow of ¥294,104,131.83[26] Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,855[12] - The largest shareholder, Shanghai Anxu Information Technology Co., Ltd., holds 68,082,885 shares, accounting for 32.34% of the total shares[12] - The second-largest shareholder, Junxin (Shanghai) Equity Investment Fund Management Co., Ltd., holds 15,042,334 shares, representing 7.14%[12] Research and Development - Research and development expenses for Q3 2024 totaled ¥60,250,924.78, a decrease of 5.15% year-over-year, representing 10.69% of revenue, down 2.14 percentage points[6] - Research and development expenses for the first three quarters of 2024 were CNY 172,412,405.70, slightly up from CNY 171,910,538.46 in 2023[22] Incentive Plans - The company adjusted the grant price of the 2022 restricted stock incentive plan from RMB 55.58 per share to RMB 39.59 per share[14] - The total number of unvested restricted stocks for the 2022 plan was adjusted from 837,415 shares to 1,172,381 shares[14] - The company approved the first unlock period for the 2023 restricted stock incentive plan, allowing 119,000 shares to be unlocked, which is 0.06% of the total share capital[15] - The number of restricted stocks available for allocation in the incentive plan was adjusted to 386,610 shares after two participants forfeited their rights[17] Other Financial Metrics - The weighted average return on equity increased to 2.73%, up 1.78 percentage points from the previous year, while year-to-date it was 5.49%, an increase of 0.54 percentage points[6] - Other comprehensive income after tax for Q3 2024 was CNY 14,035,099.29, significantly higher than CNY 2,701,650.75 in Q3 2023[23] - The company reported an investment loss of CNY 5,034,621.27 for the first three quarters of 2024, compared to a loss of CNY 2,671,345.29 in the same period of 2023[22]